Ifenprodil – Conquering Chronic Cough Starts in the Brain
Grey Matters’ chronic cough drug Ifenprodil, which works by stopping cough in the brain, was sold on March 27, 2024, to Seyltx Inc. for USD $2M cash and a 20% equity position in the company. Seyltx is a private U.S. based drug development company that continues to advance research on the drug and is planning Phase 2 trials in 2026. For more information visit www.seyltx.com
